Status:
UNKNOWN
Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy
Lead Sponsor:
Guangzhou General Hospital of Guangzhou Military Command
Conditions:
Brain Tumors
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Effect of sugammadex for reversal of rocuronium-induced neuromuscular block on Perioperative Management of awake Craniotomy
Eligibility Criteria
Inclusion
- Age: 18-45 years old body mass index (BMI)≥ 18.5-23.9 kg/m2, ASA grade I \~II.
Exclusion
- Suffering from a mental illness or preoperative communication disorder, patients with claustrophobia, breathing, circulation, neuromuscular system and kidney, and other important viscera function disorder, pregnant or lactating women, a history of malignant hyperthermia, the history of drug allergy in the process of general anesthesia and recent may not used to the interaction between rocuronium, vecuronium bromide reacts drugs (such as aminoglycoside antibiotics, Anticonvulsant, magnesium).
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05202899
Start Date
September 1 2020
End Date
May 31 2022
Last Update
March 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou Military Region General Hospital, Department of Anesthesiology
Guangzhou, Guangdong, China, 510010